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Ganten et al. [1] were the first to show that 
renin may be present in the central nervous 
system. Interestingly, before that time, 
Epstein et al. [2] had already shown that 
angiotensin II (Ang II) introduced into the 
central nervous system initiates drinking. To 
my knowledge, the first experiment to show 
that central Ang II, as opposed to Ang II from 
elsewhere, was in any way related to drinking 
or any behavior was conducted by Antelman 
et al. [3]. These investigators determined if 
drinking elicited by central carbachol 
administration was dependent on the renin–
angiotensin system, not in the brain but in the 
kidney. Rats were stereotaxically implanted 
with cannulae in the medial septal nucleus 
and then screened to determine whether or 
not they drank after carbachol. After a 
suitable period, all positive cholinergic 
drinkers were randomly assigned to one of 
three experimental groups: nephrectomized 
rats, ureterally ligated rats, and sham-
operated rats. The operations were 
performed, and 9–11 h after surgery, all 
animals were stimulated with carbachol and 
given a 1-h drinking test. There was no effect 
of nephrectomy on cholinergic drinking. The 
renal Ang II had nothing to do with drinking. 
Thus, the Ang II resulting in drinking behavior 
had to come from elsewhere, produced 
locally in the brain for instance. Schinke et 
al. [4] elucidated the issue further. They 
generated a transgenic rat that expressed an 
antisense RNA against angiotensinogen (AGT) 
mRNA specifically in the brain, namely, the 
TGR(ASrAOGEN). The rats had lower blood 
pressure than controls. When Ang II was 
injected into their brains, their drinking 
response was attenuated. The rats also had a 
defect in generating a concentrated urine and 
were relatively deficient in their ability to 
release vasopressin. 
Recently, Sakai et al. [5] generated double-
transgenic mice expressing human renin 
(hREN) from a neuron-specific promoter and 
human AGT (hAGT) from its own promoter 
(SRA mice) to emulate this expression [4]. SRA 
mice exhibited an increase in water and salt 
intake and urinary volume, which were 
significantly reduced after chronic 
intracerebroventricular delivery of losartan. 
Ang II-like immunoreactivity was markedly 
increased in the subfornical organ (SFO). To 
further evaluate the physiological importance 
of de novo Ang II production specifically in 
the SFO, the authors utilized a transgenic 
mouse model expressing a floxed version of 
hAGT, hAGT(flox), so that deletions could be 
induced with Cre recombinase. They then 
targeted SFO-specific ablation of hAGT(flox) 
by microinjection of an adenovirus encoding 
Cre recombinase. The SRA(flox) mice 
exhibited a marked increase in drinking at 
baseline and a significant decrease in water 
intake after administration of 
AdCre/adenovirus encoding enhanced green 
fluorescent protein (GFP; AdCre/AdEGFP) but 
not after administration of AdEGFP alone. 
This decrease only occurred when Cre 
recombinase correctly targeted the SFO and 
correlated with a loss of hAGT and 
angiotensin–peptide immunostaining in the 
SFO. Sakai et al. provided strong gene-related 
evidence implicating de novo synthesis of Ang 
II in the SFO as an integral regulator of fluid 
homeostasis. Thus, in terms of water drinking 
behavior, we have learned that Ang II is 
important, the peptide is generated locally, 
brain renin probably participates as AGT must 
be converted to Ang, and the SFO is a major 
site of the action. 
So much for water; the eccentric W. C. Fields 
never drank the stuff. Readers my age may 
know the reason why. In this issue, Sommer et 
al. [6] report on the brain renin–angiotensin 
system and ethanol consumption. Ethanol 
consumption can be programmed in rats by 
repeated cycles of exposure and withdrawal. 
The authors studied AGT, angiotensin-
converting enzyme (ACE), and the Ang II 
receptor (AT1) expression in various brain 
regions. They found that AGT expression 
increased in medial prefrontal cortex, 
particularly in astroglia. The exposure time 
required 7 weeks. ACE was then blocked in 
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of spirapril, an ACE inhibitor that is 
particularly blood–brain-barrier permeable. 
An alternative model was also studied, 
namely, the TGR(ASrAOGEN) was brought out 
of retirement. The readers will recall that the 
rat is transgenic for an antisense against AGT 
mRNA. Spirapril-treated rats and 
TGR(ASrAOGEN) drank less ethanol than 
controls. The current study is an extension of 
earlier work. Data are already available on 
Ang II-induced central signaling in terms of 
alcohol consumption. Maul et al. [7] 
characterized the role of central Ang II in 
alcohol intake first by using the same 
TGR(ASrAOGEN) rats. These rats consumed 
markedly less alcohol compared to their wild-
type controls. Second, spirapril did not 
influence the alcohol consumption in the 
TGR(ASrAOGEN), but it significantly reduced 
alcohol intake in wild-type rats. Furthermore, 
the dopamine concentration in the ventral 
tegmental area (VTA) was markedly reduced 
in rats with low central Ang II, suggesting a 
role for dopaminergic transmission in Ang II-
controlled alcohol preference. 
What is the connection between alcohol 
intake and the renin–angiotensin system or 
with hypertension? An association between 
hypertension and alcohol abuse has long been 
recognized, and manipulations of the renin–
angiotensin system in laboratory animals has 
been shown to alter their consumption of 
ethanol [8]. Procedures that decrease the 
renin–angiotensin system increase ethanol 
consumption. Paradoxically, inhibitors of 
angiotensin converting enzyme also diminish 
drinking. Several possible explanations for 
this observation have been proposed. 
However, observations on the relationship 
between stress-induced drinking and the 
antidipsogenic action of a fragment of 
adrenocorticotropic hormone suggest another 
possibility. ACE may be involved in the 
metabolism of this peptide and thereby could 
also exert a non-Ang II-related influence on 
drinking behavior. 
Nonetheless, clinicians know that for control 
of hypertension, cessation or at least 
reduction in alcohol intake is a first step in 
treatment [9]. Pharmacologic treatment 
should be withheld until after 2–4 weeks of 
abstinence from alcohol. Alcoholism can 
result in autonomic neuropathy and 
cardiomyopathy that can lead to a fall in 
blood pressure. Prevailing evidence suggests 
that ACE inhibitors may be the most 
appropriate pharmacologic treatment for 
alcohol-addicted patients. 
The brain renin–angiotensin system (►Fig. 1) 
appears here to stay [10]. Exactly how renin 
figures into the equation remains difficult to 
say. A splice variant appears to be expressed 
particularly in brain [11]. However, 
documenting the existence of the functioning 
protein and showing its central action has 
been fiendishly difficult. Nevertheless, two 
groups have shown in the mouse [12] and in 
the rat (Gratze et al., unpublished 
observations, 2007) that rodents transgenic 
solely for the human renin gene (hREN) 
exhibit polyphagia and become obese, 
compared to controls. Eating, as is drinking, 
would appear to be a central behavior. hREN 
has no preferred mouse or rat substrate to 
our knowledge. Whether or not Ang II is the 
final mediator of any central nervous system 
responses is also unclear. Strong argument 
has been made for a central aminopeptidase 
that degrades Ang II to the heptapeptide Ang 
[2–8], which is also known as Ang III. Fournie-
Zaluski et al. [13] reported that brain Ang III 
exerts a tonic stimulatory effect on blood 
pressure in the desoxycorticosterone (DOCA)-
salt rat that is characterized by a depressed 
systemic but a hyperactive brain renin–
angiotensin system. The group developed 
RB150, a prodrug of the specific and selective 
aminopeptidase A (APA) inhibitor, EC33. 
RB150 is able to cross the blood–brain barrier 
to inhibit brain APA and to block the 
formation of central Ang III. A single dose of 
systemic RB150 markedly reduced blood 
pressure for up to 24 h in these rats. Drugs 
that influence the renin–angiotensin system in 
the brain could be of great interest. AT1 
receptor blockers penetrate only modestly. 
Spirapril seems the best ACE inhibitor in that 
regard. Little information is available on the 
direct renin inhibitor, aliskiren. The drug is 
very hydrophilic and is a substrate for P-
glycoprotein so its central effects may be 
modest. In any event, the brain renin–
angiotensin system continues to remain heady 
stuff. 
Respectfully, 
Friedrich C. Luft 
 
Corresponding Author 
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►Fig.1. In the brain, Ang II exerts effects on drinking, salt appetite, ethanol intake, and blood 
pressure. Since AGT central nervous system depletion exerts an effect, renin seems to be necessary 
and Ang II is probably generated locally rather than being taken up from the circulation. Renin may 
exert an independent effect on eating behaviors. The subfornical ogan (SFO) seems well worked out 
as an Ang II-regulated thirst center. 
 
